SCHEMBL4395345

SCHEMBL4395345

Cc1cccc(-n2c(-c3cc(-c4ccc(S(C)(=O)=O)cc4)c(N4CCOCC4)s3)nc3ccccc3c2=O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JUN P05412 1/20 0.61
NFKB1 P19838 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
PLA2G1B P04054 1/20 0.50
HPGD P15428 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
ALDH1A1 P00352 3/20 0.47
POLB P06746 3/20 0.47
GAA P10253 2/20 0.42
MAPT P10636 3/20 0.41
TP53 P04637 2/20 0.41
TDO2 P48775 2/20 0.40
IDO2 Q6ZQW0 2/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4395538 0.94 JUN (0.68) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4395357 0.92 JUN (0.68) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4404080 0.92 JUN (0.69) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4393378 0.92 JUN (0.59) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4394371 0.90 JUN (0.64) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4393436 0.90 JUN (0.75) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4395401 0.89 JUN (0.66) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4396108 0.88 JUN (0.62) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4400315 0.88 JUN (0.64) JUNNFKB1NFKB2RELAKMT2A
SCHEMBL4398262 0.87 JUN (0.59) JUNNFKB1NFKB2RELAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829014-B2 Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2014-09-09 US disclosed
US-20120283268-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers GIORDANO ANTHONY (US) 2012-11-08 US disclosed
US-8217037-B2 Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2012-07-10 US disclosed
US-20090306073-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers B.V. PATEL PHARMACEUTICAL EDUCATION & RESEARCH DEVELOPMENT (PERD) CENTRE (IN) 2009-12-10 US disclosed
EP-2007393-A2 THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College (US) 2008-12-31 EP disclosed
WO-2007118149-A2 THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL LOLLEGE (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306073-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers TPMT, TST, SSB JUN 2228/4885NFKB1 1188/4885NFKB2 1441/4885
US-20120283268-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers TPMT, TST, SSB JUN 2228/4885NFKB1 1188/4885NFKB2 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.